Every night, millions of people stop breathing — repeatedly. Their sleep is fragmented by dozens or even hundreds of episodes where the airway collapses, oxygen levels plummet, and the brain triggers a brief arousal to restore breathing. These people often don’t remember waking, but their bodies bear the consequences: surging stress hormones, spiking blood pressure, disrupted metabolism, and chronic oxygen deprivation that damages virtually every organ system.

This is sleep apnea — one of the most common and most underdiagnosed conditions in modern medicine. An estimated 30 million Americans have obstructive sleep apnea (OSA), yet approximately 80% remain undiagnosed. Many dismiss their symptoms as normal aging, stress, or simply “not being a morning person.” Others don’t realize they have symptoms at all — their bed partners are often the first to notice the gasping, choking, and breathing pauses that characterize the condition.

The consequences of untreated sleep apnea extend far beyond daytime sleepiness. Sleep apnea is now recognized as a major driver of cardiovascular disease, hypertension, type 2 diabetes, metabolic syndrome, and a host of other serious conditions. The repeated cycles of oxygen deprivation and reoxygenation create oxidative stress and systemic inflammation. The sleep fragmentation disrupts hormonal regulation, including cortisol, growth hormone, testosterone, and the hormones controlling appetite and metabolism.

These effects are visible in blood work. People with untreated sleep apnea often show elevated inflammatory markers, abnormal glucose metabolism, dyslipidemia, elevated liver enzymes, hormonal imbalances, and elevated red blood cell counts as the body tries to compensate for chronic hypoxia. Recognizing these patterns can prompt sleep evaluation in individuals who might not otherwise be tested.

The good news is that sleep apnea is highly treatable. Continuous positive airway pressure (CPAP) therapy, the gold standard treatment, eliminates apneas and restores normal sleep architecture. Treatment improves daytime alertness, reduces blood pressure, improves glucose control, and may reduce cardiovascular risk. For many individuals, CPAP therapy is transformative — they describe feeling like a different person once they’re finally sleeping properly.

Beyond CPAP, treatment options include oral appliances, positional therapy, weight loss, and surgical interventions. The approach depends on the severity of sleep apnea, anatomical factors, and individual preferences. What matters most is that sleep apnea is identified and treated — the untreated condition carries serious and progressive health risks.

This guide explains the pathophysiology of sleep apnea, its profound effects on metabolic and cardiovascular health, the diagnostic process, and the range of treatment options available.

Quick Summary:

• Sleep apnea affects ~30 million Americans — but 80% are undiagnosed
• Obstructive sleep apnea (OSA) is the most common type — caused by airway collapse during sleep
• Key symptoms: Loud snoring, witnessed apneas, gasping/choking during sleep, excessive daytime sleepiness, morning headaches, unrefreshing sleep
• Risk factors: Obesity (strongest factor), male sex, age, neck circumference, craniofacial anatomy, family history
• Far more than snoring: Drives hypertension, arrhythmias, heart failure, stroke, type 2 diabetes, metabolic syndrome
• Blood work clues: Elevated HbA1c, dyslipidemia, elevated CRP, elevated liver enzymes, low testosterone, elevated hemoglobin/hematocrit (polycythemia)
• Diagnosis: Sleep study (polysomnography or home sleep apnea test) — measures apneas, hypopneas, and oxygen levels
• AHI (Apnea-Hypopnea Index): Number of breathing events per hour — defines severity
• Treatment: CPAP is gold standard; alternatives include oral appliances, positional therapy, weight loss, surgery
• Treatment benefits: Improved alertness, lower blood pressure, better glucose control, improved quality of life
• Bidirectional relationships: Sleep apnea worsens metabolic disease; metabolic disease worsens sleep apnea

---

Understanding Sleep Apnea

Types of Sleep Apnea

Sleep apnea refers to repeated episodes of breathing cessation during sleep. There are three main types:

Obstructive Sleep Apnea (OSA): By far the most common type, accounting for approximately 84% of cases. OSA occurs when the upper airway repeatedly collapses during sleep, blocking airflow despite continued respiratory effort. The brain senses the resulting hypoxia and briefly arouses the sleeper enough to restore muscle tone and reopen the airway. These arousals fragment sleep architecture, even when the person doesn’t consciously wake.

Central Sleep Apnea (CSA): A less common type where the brain fails to send proper signals to the breathing muscles. The airway isn’t blocked — the respiratory drive simply pauses. CSA is associated with heart failure, stroke, opioid use, and high-altitude exposure. Some individuals have both obstructive and central components.

Complex/Mixed Sleep Apnea: Initially presents as obstructive sleep apnea but reveals significant central apneas when obstruction is treated with CPAP. Also called treatment-emergent central sleep apnea.

This guide focuses primarily on obstructive sleep apnea, the most prevalent form.

What Happens During an Apnea

During normal sleep, the muscles that hold the airway open relax somewhat. In people with OSA, this relaxation allows the airway to narrow significantly or collapse completely. When airflow stops (apnea) or is substantially reduced (hypopnea), several things happen:

1. Oxygen levels drop: Without airflow, blood oxygen saturation falls — sometimes dramatically, into ranges that would be alarming in awake individuals.
2. Carbon dioxide rises: Without gas exchange, CO2 accumulates in the blood.
3. Respiratory effort increases: The chest and diaphragm work harder against the closed airway, creating negative intrathoracic pressure.
4. The brain triggers arousal: Sensing hypoxia and hypercapnia, the brain initiates a brief awakening — just enough to restore airway muscle tone and resume breathing.
5. Breathing resumes: Often with a gasp or snort. Oxygen levels recover, CO2 is exhaled.
6. Sleep resumes: Until the next event, which may occur within seconds to minutes.

In severe sleep apnea, this cycle may repeat 30, 60, or even 100+ times per hour. Even in moderate cases, hundreds of events may occur per night. Each arousal triggers a surge of sympathetic nervous system activity — the “fight or flight” response — with accompanying increases in heart rate, blood pressure, and stress hormone release.

Measuring Severity: The AHI

Sleep apnea severity is quantified by the Apnea-Hypopnea Index (AHI): the average number of apneas and hypopneas per hour of sleep.

AHI (events/hour)	Severity Classification
Less than 5	Normal
5-14	Mild OSA
15-29	Moderate OSA
30 or more	Severe OSA

Oxygen desaturation index (ODI) and time spent below certain oxygen thresholds also contribute to severity assessment. Some individuals have relatively few events but profound oxygen desaturations; others have many events with minimal desaturation. Both patterns carry health risks.

---

Causes and Risk Factors

Anatomical Factors

The size and shape of the upper airway influence OSA risk:

Obesity: The strongest risk factor for OSA. Excess weight deposits fat around the upper airway, narrowing it and increasing its collapsibility. Fat deposition in the tongue (yes, tongues get fat) is particularly problematic. Obesity also reduces lung volumes, which affects the tethering forces that help keep the airway open. Approximately 70% of people with OSA are obese, and weight gain significantly increases OSA risk.

Neck circumference: A thick neck (greater than 17 inches in men, 16 inches in women) correlates with increased soft tissue around the airway. Neck circumference is an independent predictor of OSA even after accounting for BMI.

Craniofacial anatomy: Structural features that narrow the airway increase risk: retrognathia (recessed jaw), large tongue (macroglossia), large tonsils, elongated soft palate, deviated septum, and nasal obstruction. These factors explain why some non-obese individuals develop OSA.

Age: Airway muscle tone decreases with age, and fat redistribution to the upper body increases. OSA prevalence increases substantially with age, though severe obesity can cause OSA even in young adults.

Sex: Men are 2-3 times more likely to have OSA than premenopausal women. This gap narrows after menopause, suggesting hormonal influences. Men tend to have more upper body fat distribution and different airway anatomy.

Other Risk Factors

Family history: OSA runs in families, reflecting shared anatomical features and possibly genetic factors affecting airway control and obesity susceptibility.

Alcohol and sedatives: These substances relax airway muscles, increasing collapsibility. Alcohol before bed can dramatically worsen OSA severity even in people with mild disease.

Smoking: Increases upper airway inflammation and fluid retention, narrowing the airway. Smokers have higher OSA risk than non-smokers.

Nasal congestion: Chronic nasal obstruction from allergies, polyps, or deviated septum increases negative pressure needed to breathe, promoting airway collapse.

Supine sleep position: Sleeping on the back worsens airway collapse in many people due to gravitational effects on the tongue and soft palate. Some individuals have positional OSA — significant apnea only when supine.

Medical conditions: Hypothyroidism (causes tissue swelling and weight gain), acromegaly (enlarges tongue and soft tissue), and certain syndromes (Down syndrome, Marfan syndrome) increase OSA risk.

The Obesity-Sleep Apnea Cycle

The relationship between obesity and sleep apnea is bidirectional and self-reinforcing:

• Obesity causes sleep apnea through mechanical and inflammatory mechanisms
• Sleep apnea promotes weight gain through hormonal disruption (increased ghrelin, decreased leptin), fatigue reducing exercise capacity, and metabolic changes favoring fat storage
• Weight gain worsens sleep apnea
• Worse sleep apnea further promotes weight gain

Breaking this cycle — through weight loss, OSA treatment, or both — can have profound health benefits.

---

Symptoms and Signs

Nocturnal Symptoms

Snoring: Loud, habitual snoring is the hallmark symptom. The snoring of OSA is often crescendo-pattern, ending with a silence (the apnea) followed by a gasp or snort. However, not everyone who snores has sleep apnea, and not everyone with sleep apnea snores (particularly women, who may present differently).

Witnessed apneas: Bed partners often observe breathing pauses that end with gasping or choking. This is highly specific for OSA — people whose partners witness apneas almost certainly have the condition.

Gasping or choking during sleep: Some individuals wake themselves with the sensation of choking or inability to breathe.

Restless sleep: Frequent position changes, thrashing, or active sleep.

Nocturia: Frequent nighttime urination. The cardiac and hormonal effects of apneas increase urine production. Many individuals attribute nocturia to prostate problems or aging but find it resolves with OSA treatment.

Night sweats: The sympathetic activation accompanying apneas can cause sweating.

Insomnia: Some individuals (particularly women) present with difficulty maintaining sleep rather than classic snoring-and-gasping.

Daytime Symptoms

Excessive daytime sleepiness: The cardinal daytime symptom. Individuals may fall asleep during passive activities (watching TV, reading), while driving (dangerous), or even during conversation. Some individuals don’t recognize their sleepiness as abnormal — they’ve felt this way for so long it seems normal.

Unrefreshing sleep: Despite adequate time in bed, individuals wake feeling tired, as if they haven’t slept.

Morning headaches: Carbon dioxide retention during sleep causes vasodilation and headache upon waking.

Cognitive impairment: Difficulty concentrating, memory problems, reduced attention span. The sleep fragmentation and intermittent hypoxia impair cognitive function.

Mood changes: Irritability, depression, and anxiety are common. Sleep apnea is often misdiagnosed as depression alone.

Decreased libido and sexual dysfunction: Hormonal disruption (low testosterone) and fatigue reduce sexual interest and function.

Signs on Examination

Physical findings that suggest OSA risk:

• Obesity, particularly central obesity
• Large neck circumference
• Crowded oropharynx (Mallampati class III or IV)
• Enlarged tonsils
• Large tongue
• Retrognathia (small, recessed jaw)
• Nasal obstruction
• Hypertension (especially resistant hypertension)

---

Health Consequences

Untreated sleep apnea affects virtually every organ system. The mechanisms include intermittent hypoxia, oxidative stress, systemic inflammation, sympathetic nervous system activation, sleep fragmentation, and hormonal disruption. What makes sleep apnea particularly insidious is that individuals often don’t realize these health effects are connected to their sleep.

Cardiovascular Disease

The cardiovascular consequences of OSA are profound and represent the most clinically significant health impact:

Hypertension: OSA is the most common identifiable cause of secondary hypertension. The repeated surges of sympathetic activity during apneas raise blood pressure acutely — with each apnea, blood pressure can spike dramatically. Over time, these repeated surges reset the baseline higher, leading to sustained hypertension even during wakefulness. Approximately 50% of OSA individuals have hypertension; conversely, 30-80% of individuals with resistant hypertension (uncontrolled despite three or more medications) have OSA. The nocturnal blood pressure pattern is particularly affected — normally blood pressure “dips” during sleep, but OSA individuals often show non-dipping or even reverse-dipping patterns, which carry increased cardiovascular risk. Treatment of OSA typically reduces blood pressure, though the effect varies (average reduction of several mmHg).

Arrhythmias: The autonomic swings during apneas — rapid shifts between parasympathetic and sympathetic dominance — create an arrhythmogenic environment. Atrial fibrillation is 2-4 times more common in OSA individuals, and OSA makes atrial fibrillation harder to treat. The risk of nocturnal sudden cardiac death is elevated in OSA, with a characteristic pattern of cardiac events during sleeping hours (midnight to 6 AM) rather than the morning peak seen in the general population. Treating OSA reduces arrhythmia burden and improves outcomes after atrial fibrillation treatment.

Coronary artery disease: OSA independently increases heart attack risk through multiple mechanisms: sustained hypertension, systemic inflammation, endothelial dysfunction, accelerated atherosclerosis, increased platelet aggregation, and oxidative stress. The intermittent hypoxia of OSA resembles ischemia-reperfusion injury occurring hundreds of times per night. OSA worsens outcomes after acute coronary events and is present in the majority of acute coronary syndrome individuals.

Heart failure: OSA places mechanical stress on the heart through negative intrathoracic pressure swings (the heart works harder against increased pressure gradients) and increases afterload through hypertension. Over time, this can lead to left ventricular hypertrophy and both systolic and diastolic dysfunction. Heart failure is more common in OSA individuals, and the relationship is bidirectional — heart failure itself can cause or worsen central sleep apnea through respiratory control instability.

Stroke: OSA increases stroke risk 2-3 fold, independent of other cardiovascular risk factors. Mechanisms include hypertension, atrial fibrillation, hypercoagulability, endothelial dysfunction, and unstable atherosclerotic plaques. OSA also worsens outcomes after stroke, impairing neurological recovery. Notably, OSA is extremely common in stroke individuals — present in 50-70% — and treatment may improve rehabilitation outcomes.

Pulmonary hypertension: Chronic intermittent hypoxia causes pulmonary vasoconstriction. Over time, this can lead to sustained pulmonary hypertension and right heart strain, particularly in individuals with severe OSA or coexisting lung disease.

Metabolic Dysfunction

OSA has profound effects on glucose and lipid metabolism that are increasingly recognized as central to its health impact:

Insulin resistance and type 2 diabetes: OSA independently causes insulin resistance through multiple, complementary mechanisms. Intermittent hypoxia directly impairs insulin signaling in fat, muscle, and liver tissue — this effect is seen even in lean individuals and occurs independent of obesity. Sleep fragmentation disrupts glucose regulation through effects on the autonomic nervous system and cortisol. Sympathetic activation raises glucose through stress hormone effects. Inflammatory cytokines (IL-6, TNF-alpha, CRP) interfere with insulin action. The cumulative effect is significant: OSA individuals have 2-3 times higher risk of developing type 2 diabetes, even after controlling for obesity and other factors. For individuals who already have diabetes, OSA makes glycemic control more difficult. Treatment of OSA can improve insulin sensitivity and modestly improve HbA1c levels.

Metabolic syndrome: OSA is now considered by some researchers to be a core component of metabolic syndrome rather than merely an associated condition. The clustering of OSA with central obesity, hypertension, dyslipidemia, and insulin resistance is striking — these conditions share common pathophysiology and each worsens the others. The term “Syndrome Z” has been proposed to recognize OSA’s integral role in metabolic dysfunction.

Dyslipidemia: OSA is associated with an atherogenic lipid profile: elevated triglycerides, elevated LDL cholesterol, and reduced HDL cholesterol. Intermittent hypoxia appears to directly affect hepatic lipid metabolism, promoting triglyceride synthesis and VLDL secretion. These lipid abnormalities contribute to cardiovascular risk and may improve with OSA treatment.

Non-alcoholic fatty liver disease: OSA increases NAFLD risk and accelerates progression to non-alcoholic steatohepatitis (NASH) and fibrosis. The intermittent hypoxia appears to directly promote hepatic fat accumulation, oxidative stress, and inflammatory injury. Severity of OSA correlates with severity of liver disease. Treating OSA may slow liver disease progression.

Hormonal Effects

Testosterone: OSA suppresses testosterone levels in men through effects on the hypothalamic-pituitary-gonadal axis. The sleep fragmentation disrupts the normal nocturnal testosterone surge. Men with OSA commonly have low testosterone; treatment of OSA can improve levels.

Growth hormone: Growth hormone is normally released in pulses during deep sleep. Sleep fragmentation from OSA disrupts this pattern, potentially affecting body composition, metabolism, and tissue repair.

Cortisol: The repeated arousals and sympathetic activation in OSA create a state of chronic stress with elevated cortisol, contributing to metabolic dysfunction and mood disorders.

Appetite hormones: OSA increases ghrelin (hunger hormone) and decreases leptin (satiety hormone), promoting increased food intake and weight gain.

Thyroid: OSA is more common in hypothyroidism, and hypothyroidism can worsen OSA. The relationship is complex and may involve both metabolic and mechanical factors.

Other Health Effects

Cognitive impairment: Chronic intermittent hypoxia damages brain tissue, particularly in areas important for memory and executive function. OSA is associated with accelerated cognitive decline and increased dementia risk.

Depression and mood disorders: The relationship is bidirectional. OSA causes depression through sleep disruption and neurological effects; depression may worsen sleep patterns. OSA should be considered in depressed individuals, especially those with risk factors.

Motor vehicle accidents: Sleepiness from OSA dramatically increases accident risk — estimates suggest 2-7 times higher crash risk. Treating OSA reduces this risk.

Surgical and anesthetic risk: OSA individuals have increased risk of perioperative complications, including difficult intubation, respiratory depression, and cardiac events.

Mortality: Severe untreated OSA is associated with increased all-cause mortality, driven primarily by cardiovascular causes.

---

Effects on Blood Work

Sleep apnea often leaves fingerprints in routine laboratory testing. Recognizing these patterns can prompt sleep evaluation in at-risk individuals.

Glucose and Metabolic Markers

Elevated fasting glucose and HbA1c: OSA causes insulin resistance independent of obesity. Individuals with unexplained prediabetes or difficult-to-control diabetes should be evaluated for OSA.

Elevated fasting insulin: Reflects insulin resistance, often preceding glucose abnormalities.

HOMA-IR: Calculated measure of insulin resistance that may be elevated even when glucose appears normal.

Lipid Panel

Elevated triglycerides: Common finding in OSA, particularly in individuals with coexisting obesity and metabolic syndrome.

Low HDL cholesterol: Part of the atherogenic dyslipidemia pattern associated with OSA.

Elevated LDL cholesterol: May be present, contributing to cardiovascular risk.

Inflammatory Markers

Elevated CRP: The intermittent hypoxia and oxidative stress of OSA create chronic systemic inflammation. High-sensitivity CRP is often elevated and may fall with treatment.

Elevated IL-6, TNF-alpha: Research markers that are elevated in OSA, though not typically measured clinically.

Liver Enzymes

Elevated ALT and AST: OSA is associated with non-alcoholic fatty liver disease and can directly cause liver enzyme elevation through hypoxic liver injury. Elevated liver enzymes in an obese individual should prompt consideration of both NAFLD and OSA.

Complete Blood Count

Elevated hemoglobin and hematocrit (polycythemia): The body responds to chronic hypoxia by producing more red blood cells. Elevated hemoglobin/hematocrit, particularly in an obese individual, should raise suspicion for OSA. This is a compensatory mechanism but increases blood viscosity and thrombotic risk.

Elevated red blood cell count: Accompanies the polycythemia response.

Hormonal Testing

Low testosterone: Common in men with OSA. Fatigue, low libido, and low testosterone in an overweight man should prompt sleep evaluation — treating OSA may improve testosterone without requiring testosterone replacement.

Elevated prolactin: May be mildly elevated in some OSA individuals.

Abnormal thyroid function: Hypothyroidism is more common in OSA individuals and can worsen the condition.

Other Markers

Elevated uric acid: Associated with OSA, possibly related to hypoxia effects on purine metabolism. The association with metabolic syndrome and hypertension adds complexity.

Elevated BNP or NT-proBNP: May be elevated due to cardiac strain from OSA, particularly in individuals developing heart failure.

Microalbuminuria: OSA is associated with early kidney dysfunction, possibly through hypertension and metabolic effects.

---

Diagnosis

Clinical Assessment

Diagnosis begins with clinical suspicion based on symptoms and risk factors. Screening questionnaires help identify high-risk individuals:

STOP-BANG questionnaire: Evaluates Snoring, Tiredness, Observed apneas, high blood Pressure, BMI, Age, Neck circumference, and Gender. Scores of 3 or higher indicate elevated OSA risk.

Epworth Sleepiness Scale: Measures subjective daytime sleepiness by asking about likelihood of dozing in various situations. Scores above 10 suggest excessive sleepiness.

Sleep Studies

Definitive diagnosis requires objective sleep testing:

Polysomnography (PSG): The gold standard. Performed overnight in a sleep laboratory, PSG monitors brain waves (EEG), eye movements (EOG), muscle activity (EMG), heart rhythm (ECG), breathing effort, airflow, oxygen saturation, body position, and leg movements. It identifies apneas, hypopneas, oxygen desaturations, arousals, and sleep stages. PSG can diagnose all types of sleep apnea and other sleep disorders.

Home Sleep Apnea Test (HSAT): A simplified test performed at home, typically monitoring airflow, breathing effort, and oxygen saturation. HSAT is appropriate for individuals with high pretest probability of moderate-to-severe OSA without significant comorbidities. It’s more convenient and less expensive than PSG but may underestimate severity and misses other sleep disorders. Negative or inconclusive HSAT in a symptomatic individual should prompt in-laboratory PSG.

What the Sleep Study Shows

Key metrics from sleep studies include:

Apnea-Hypopnea Index (AHI): The number of apneas (complete breathing cessation) plus hypopneas (partial airway obstruction with oxygen desaturation or arousal) per hour of sleep. Defines diagnosis and severity.

Oxygen Desaturation Index (ODI): Number of oxygen desaturations (typically ≥3% or ≥4% drop) per hour.

Minimum oxygen saturation: The lowest oxygen level recorded during the study.

Time below 90% saturation: Cumulative time spent with oxygen below 90%.

Sleep architecture: The distribution of sleep stages. OSA often reduces deep sleep and REM sleep.

Arousal index: Number of arousals (brief awakenings) per hour.

Additional Evaluation

Depending on findings and clinical picture:

Blood tests: Thyroid function (hypothyroidism can cause or worsen OSA), metabolic panel, lipids, HbA1c (screen for associated conditions).

Cardiac evaluation: EKG, echocardiogram if heart failure or pulmonary hypertension suspected.

ENT evaluation: Examination of nasal passages, oropharynx, and larynx if anatomical factors need assessment or surgical treatment is considered.

---

Treatment

Effective treatment for sleep apnea exists and can be transformative. The goals are to eliminate apneas and hypopneas, normalize oxygen levels, restore consolidated sleep, relieve symptoms, and reduce long-term health consequences. Treatment selection depends on severity, individual anatomy, comorbidities, and preferences.

Continuous Positive Airway Pressure (CPAP)

CPAP is the gold standard treatment for moderate-to-severe OSA and is highly effective when used consistently.

How it works: A CPAP machine delivers constant positive air pressure through a mask worn during sleep. This positive pressure acts as a pneumatic splint, keeping the upper airway open throughout the breathing cycle regardless of muscle relaxation. Airflow is normalized, apneas are eliminated, oxygen levels are maintained, and sleep is no longer fragmented by arousals. The pressure required varies by individual and is determined during a titration study or by auto-adjusting (APAP) devices.

Effectiveness: CPAP is highly effective when used consistently — it essentially eliminates OSA while being worn. Benefits include: complete elimination of apneas and hypopneas, normalization of oxygen levels, restoration of normal sleep architecture with increased deep and REM sleep, dramatic improvement in daytime sleepiness (Epworth Sleepiness Scale scores typically normalize), reduction in blood pressure (average 2-3 mmHg, more in those with resistant hypertension), improvement in insulin sensitivity and glycemic control, improved quality of life, reduced cardiovascular event risk, and improved cognitive function. Many individuals experience dramatic improvement from the first night of properly titrated CPAP — they describe it as revelatory, feeling rested for the first time in years.

Adherence challenges: The main limitation of CPAP is adherence. Studies show that 30-50% of individuals struggle with long-term use. Common complaints include: mask discomfort or poor fit, claustrophobia, nasal dryness, congestion, or rhinorrhea, skin irritation or pressure sores, aerophagia (swallowing air), difficulty tolerating pressure (particularly during exhalation), noise disturbance (though modern machines are quiet), inconvenience for travel, and aesthetic concerns. These barriers are real but often surmountable with proper support.

Optimizing success: Multiple strategies improve CPAP adherence: proper mask fitting (many styles exist — nasal pillows, nasal masks, full face masks — and finding the right one is crucial), heated humidification (reduces nasal dryness and congestion), pressure ramping (gradual pressure increase at sleep onset), APAP/auto-titrating machines (adjust pressure automatically, often more comfortable), expiratory pressure relief (reduces pressure during exhalation), education about benefits and techniques, early follow-up to address problems (first weeks are critical), treatment of nasal congestion (nasal steroids, allergy treatment), and cognitive behavioral therapy for those with claustrophobia or anxiety. Individuals who persist through the first few weeks usually adapt and become committed users — they feel so much better that CPAP becomes non-negotiable.

Monitoring adherence: Modern CPAP machines track usage, allowing clinicians to monitor adherence and residual AHI. This data helps troubleshoot problems and optimize therapy. Insurance coverage often requires documented adherence.

Oral Appliances

Custom-fitted dental devices that reposition the jaw forward (mandibular advancement devices or MADs) can open the airway and reduce apneas.

Mechanism: By advancing the mandible forward, oral appliances increase the space in the posterior pharynx, reduce airway collapsibility, and decrease the severity of obstruction. They also stabilize the tongue position.

Indications: Mild-to-moderate OSA (first-line alternative to CPAP), individuals who cannot tolerate or refuse CPAP, individuals who prefer a non-device option, primary snoring without significant OSA, positional OSA, and combination therapy with CPAP (occasionally).

Effectiveness: Oral appliances are less effective than CPAP at reducing AHI — typical AHI reduction is 50% compared to near-complete elimination with CPAP. However, better adherence (people are more likely to use them consistently) may result in similar real-world clinical outcomes for some individuals. Response varies considerably — oral appliances work best for mild-to-moderate OSA, positional OSA, younger individuals, individuals with normal BMI, and those with certain anatomical features. A follow-up sleep study should confirm efficacy.

Considerations: Requires fitting by a dentist with sleep medicine expertise. Cost is significant. Side effects include jaw discomfort, temporomandibular joint (TMJ) pain, excessive salivation or dry mouth, tooth movement and bite changes with long-term use, and limited efficacy in severe OSA or morbidly obese individuals.

Positional Therapy

For individuals with positional OSA — significantly worse when sleeping supine (on back) — interventions that prevent supine sleep can reduce apneas substantially.

Methods include: Positional therapy devices worn around the torso that vibrate or cause discomfort when supine, tennis balls sewn into nightshirt backs (low-tech but effective), specialized pillows, and bed positioning.

Effectiveness: Can be very effective for true positional OSA (defined as supine AHI at least twice non-supine AHI). However, positional therapy alone is typically appropriate only for mild positional OSA. It works best as adjunctive therapy combined with other treatments.

Weight Loss

Weight loss is the only treatment that addresses the underlying cause in obese individuals and should be part of management for all overweight OSA individuals.

Benefits include: Reduced AHI — substantial weight loss (10-15% of body weight) can reduce AHI by 50% or more; potential “cure” — some individuals achieve AHI below diagnostic threshold with major weight loss, essentially resolving their OSA; improved CPAP effectiveness and reduced required pressure; benefits for metabolic health, cardiovascular risk, and overall wellbeing independent of OSA treatment; and potential reduction in cardiovascular consequences.

Challenges: Weight loss sufficient to significantly impact OSA often requires intensive intervention. Lifestyle modification alone achieves modest weight loss in most people. Medical weight loss programs (medications like GLP-1 agonists) can produce meaningful weight reduction. Bariatric surgery dramatically improves OSA in most individuals — studies show average AHI reduction of 70-80% — though some residual disease often persists. The newer GLP-1 receptor agonists (semaglutide, tirzepatide) are showing promise for both weight loss and potential direct benefits on OSA.

Important: Weight loss should complement rather than replace CPAP therapy while weight loss is being achieved — untreated OSA shouldn’t wait for weight loss.

Surgical Options

Surgery aims to enlarge or stabilize the upper airway. Options include:

Uvulopalatopharyngoplasty (UPPP): Removes excess tissue from soft palate, uvula, and pharynx. Once the most common sleep apnea surgery, success rates are modest (~50% significant improvement) and results may diminish over time.

Maxillomandibular advancement (MMA): Advances both upper and lower jaws forward, substantially enlarging the airway. One of the most effective surgeries for OSA but also the most invasive. Reserved for selected individuals, particularly those with craniofacial abnormalities.

Hypoglossal nerve stimulation: An implanted device stimulates the nerve controlling tongue movement, moving the tongue forward during breathing to open the airway. Approved for individuals with moderate-to-severe OSA who cannot tolerate CPAP. Less invasive than skeletal surgery with good efficacy in selected individuals.

Nasal surgery: Correcting nasal obstruction (septoplasty, turbinate reduction, polyp removal) may improve CPAP tolerance and modestly reduce apneas.

Tonsillectomy: Highly effective in children with OSA (where enlarged tonsils are often the cause). Can help adults with very large tonsils.

Other Treatments

Avoiding alcohol and sedatives: These worsen airway collapsibility. Individuals should avoid alcohol within 3 hours of bedtime and discuss sedating medications with their physician.

Treating nasal congestion: Nasal steroids, allergy management, and treatment of chronic rhinitis can improve both OSA and CPAP tolerance.

Treating underlying conditions: Managing hypothyroidism, optimizing heart failure treatment, and addressing other contributing conditions is important.

Supplemental oxygen: Oxygen alone doesn’t treat OSA (the airway still obstructs) but may be added to CPAP in individuals with persistent hypoxemia from lung disease.

---

Special Populations

Women with Sleep Apnea

OSA has historically been underdiagnosed in women because the “classic” presentation — obese, snoring man — doesn’t always apply. Women may present differently:

• More likely to report insomnia, fatigue, and depression than witnessed apneas
• Less likely to have loud, habitual snoring
• May have lower AHI for same degree of symptoms (REM-related OSA more common)
• Prevalence increases substantially after menopause

Clinicians should maintain appropriate suspicion in women with risk factors or symptoms, even without classic presentation.

Children with Sleep Apnea

Pediatric OSA differs from adult OSA:

• Most common cause is enlarged tonsils and adenoids
• Obesity is increasingly important as childhood obesity rises
• Symptoms include snoring, restless sleep, mouth breathing, behavioral problems, and learning difficulties
• First-line treatment is adenotonsillectomy, which cures most cases
• CPAP may be needed if surgery fails or isn’t indicated

OSA and Heart Failure

Sleep apnea (both obstructive and central) is extremely common in heart failure individuals — present in 50-75%. The relationship is bidirectional: OSA worsens heart failure through hemodynamic stress; heart failure can cause central sleep apnea through respiratory control instability. Treatment with CPAP or adaptive servo-ventilation requires careful consideration and monitoring in heart failure individuals.

OSA and Pregnancy

OSA risk increases during pregnancy due to weight gain, nasal congestion, and hormonal effects on airway tissue. Untreated OSA in pregnancy is associated with significant risks: gestational hypertension, preeclampsia (2-4 times higher risk), gestational diabetes, preterm birth, low birth weight, and cesarean delivery. Screening for OSA in pregnant women with risk factors (obesity, chronic hypertension, snoring) is important. CPAP is safe and effective during pregnancy.

---

Prevention and Risk Reduction

While some OSA risk factors (anatomy, genetics, sex) cannot be modified, others can be addressed:

Weight Management

Maintaining healthy weight is the most important modifiable factor. Preventing weight gain prevents OSA development; weight loss in those who are overweight reduces OSA risk and severity. Even modest weight changes affect risk — a 10% weight gain increases AHI by approximately 30%.

Alcohol and Sedative Avoidance

Avoiding alcohol and sedating medications near bedtime prevents their airway-relaxing effects. This is particularly important for those with known risk factors or mild OSA.

Smoking Cessation

Quitting smoking reduces upper airway inflammation and edema. Former smokers have lower OSA risk than current smokers.

Treatment of Nasal Conditions

Managing allergies, chronic rhinitis, and nasal obstruction maintains nasal breathing and may reduce OSA severity.

Sleep Position

For those with positional tendency, avoiding supine sleep can prevent or reduce apneas.

Early Detection

Recognizing risk factors and symptoms early allows intervention before significant consequences develop. People with snoring, obesity, hypertension, or metabolic syndrome should be alert to OSA symptoms.

---

The Value of Testing

Why Screen for Sleep Apnea

Given its high prevalence and significant health consequences, appropriate screening for sleep apnea can identify individuals who would benefit from treatment:

• Individuals with symptoms (snoring, witnessed apneas, excessive sleepiness)
• Individuals with treatment-resistant hypertension
• Individuals with atrial fibrillation
• Individuals with type 2 diabetes, especially with poor control
• Individuals with unexplained polycythemia
• Individuals with unexplained low testosterone
• Individuals with heart failure
• Individuals before bariatric surgery
• Commercial drivers and pilots

Blood Work as a Screening Tool

While blood tests don’t diagnose sleep apnea, certain patterns should raise suspicion:

• Unexplained elevated HbA1c or difficult-to-control diabetes
• Elevated hemoglobin/hematocrit without other explanation
• Low testosterone in an obese man with fatigue
• Elevated liver enzymes with fatty liver
• Elevated CRP with metabolic syndrome features

These findings in a individual with risk factors for OSA should prompt sleep evaluation.

---

Key Takeaways

Sleep apnea is far more than a snoring problem — it’s a systemic disease with profound effects on cardiovascular, metabolic, and cognitive health. Its high prevalence combined with dramatic underdiagnosis means millions of people are suffering preventable health consequences.

Key points to remember:

• OSA affects approximately 30 million Americans; 80% are undiagnosed
• Key symptoms include snoring, witnessed apneas, excessive sleepiness, and morning headaches
• Obesity is the strongest risk factor; weight loss is part of treatment
• OSA drives hypertension, diabetes, heart disease, and stroke
• Blood work may show elevated HbA1c, polycythemia, low testosterone, elevated liver enzymes, and elevated inflammatory markers
• Diagnosis requires sleep study (polysomnography or home sleep test)
• CPAP is the gold standard treatment — highly effective when used
• Alternative treatments include oral appliances, positional therapy, and surgery
• Treatment improves symptoms, blood pressure, metabolic parameters, and quality of life
• Individuals with resistant hypertension, atrial fibrillation, difficult-to-control diabetes, or unexplained polycythemia should be evaluated for OSA

If you recognize symptoms of sleep apnea in yourself or a loved one, pursue evaluation. Effective treatment can be transformative — improving energy, cognition, mood, and long-term health outcomes.